Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Establishing a Long-Term Model for Analysis and Improvement of Underfilled Blood Culture Volumes.

Zaleski M, Erdman P, Adams J, Michael A, Rudy A, Boesch R, Allison L, Mailander P, Hess W, Myers D, Craft D.

Am J Clin Pathol. 2018 Sep 26. doi: 10.1093/ajcp/aqy125. [Epub ahead of print]

PMID:
30260386
2.

Patterns and Profiles of Adolescent Tobacco Users: Results From the Virginia Youth Survey.

Sutter ME, Everhart RS, Miadich S, Rudy AK, Nasim A, Cobb CO.

Nicotine Tob Res. 2018 Aug 14;20(suppl_1):S39-S47. doi: 10.1093/ntr/nty032.

3.

Patterns and Correlates of Tobacco and Cannabis co-use by Tobacco Product Type: Findings from the Virginia Youth Survey.

Cobb CO, Soule EK, Rudy AK, Sutter ME, Cohn AM.

Subst Use Misuse. 2018 Dec 6;53(14):2310-2319. doi: 10.1080/10826084.2018.1473437. Epub 2018 Jul 2.

PMID:
29963944
4.

Correction to: Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment.

Gouty D, Cai CC, Cai XY, Kasinath A, Kumar V, Alvandkouhi S, Yang J, Pederson S, Babbitt B, Peritt D, Rudy A, Koppenburg V, Dasilva A, Ullmann M, Liu S, Satterwhite C.

AAPS J. 2018 Feb 27;20(2):38. doi: 10.1208/s12248-018-0189-6.

PMID:
29488021
5.

Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment.

Gouty D, Cai CC, Cai XY, Kasinath A, Kumar V, Alvandkouhi S, Yang J, Pederson S, Babbitt B, Peritt D, Rudy A, Koppenburg V, Dasilva A, Ullmann M, Liu S, Satterwhite C.

AAPS J. 2017 Dec 28;20(1):25. doi: 10.1208/s12248-017-0181-6. Erratum in: AAPS J. 2018 Feb 27;20(2):38.

PMID:
29285735
6.

A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.

Weir MR, Pergola PE, Agarwal R, Fink JC, Kopyt NP, Singh AK, Kumar J, Schmitt S, Schaffar G, Rudy A, McKay JP, Kanceva R.

Am J Nephrol. 2017;46(5):364-370. doi: 10.1159/000481736. Epub 2017 Oct 30.

PMID:
29084409
7.

Assessing electronic cigarette effects and regulatory impact: Challenges with user self-reported device power.

Rudy AK, Leventhal AM, Goldenson NI, Eissenberg T.

Drug Alcohol Depend. 2017 Oct 1;179:337-340. doi: 10.1016/j.drugalcdep.2017.07.031. Epub 2017 Aug 18.

8.

Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients
.

Casadevall N, Dobronravov V, Eckardt KU, Ertürk S, Martynyuk L, Schmitt S, Schaffar G, Rudy A, Krendyukov A, Ode M.

Clin Nephrol. 2017 Oct;88(10):190-197. doi: 10.5414/CN109159.

9.

Tobacco Marketing, E-cigarette Susceptibility, and Perceptions among Adults.

Nicksic NE, Snell LM, Rudy AK, Cobb CO, Barnes AJ.

Am J Health Behav. 2017 Sep 1;41(5):579-590. doi: 10.5993/AJHB.41.5.7.

10.

Identification of a New Antibacterial Sulfur Compound from Raphanus sativus Seeds.

Jadoun J, Yazbak A, Rushrush S, Rudy A, Azaizeh H.

Evid Based Complement Alternat Med. 2016;2016:9271285. Epub 2016 Oct 3.

11.

Evanescent Field Based Photoacoustics: Optical Property Evaluation at Surfaces.

Goldschmidt BS, Rudy AM, Nowak CA, Tsay Y, Whiteside PJ, Hunt HK.

J Vis Exp. 2016 Jul 26;(113). doi: 10.3791/54192.

12.

Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.

Harbeck N, Lipatov O, Frolova M, Udovitsa D, Topuzov E, Ganea-Motan DE, Nakov R, Singh P, Rudy A, Blackwell K.

Future Oncol. 2016 Jun;12(11):1359-67. doi: 10.2217/fon-2016-0016. Epub 2016 Mar 29.

13.

Electronic cigarette use and indoor air quality in a natural setting.

Soule EK, Maloney SF, Spindle TR, Rudy AK, Hiler MM, Cobb CO.

Tob Control. 2017 Jan;26(1):109-112. doi: 10.1136/tobaccocontrol-2015-052772. Epub 2016 Feb 15.

14.

Computationally efficient autoregressive method for generating phase screens with frozen flow and turbulence in optical simulations.

Srinath S, Poyneer LA, Rudy AR, Ammons SM.

Opt Express. 2015 Dec 28;23(26):33335-49. doi: 10.1364/OE.23.033335.

PMID:
26831998
15.

Discovery and spectroscopy of the young jovian planet 51 Eri b with the Gemini Planet Imager.

Macintosh B, Graham JR, Barman T, De Rosa RJ, Konopacky Q, Marley MS, Marois C, Nielsen EL, Pueyo L, Rajan A, Rameau J, Saumon D, Wang JJ, Patience J, Ammons M, Arriaga P, Artigau E, Beckwith S, Brewster J, Bruzzone S, Bulger J, Burningham B, Burrows AS, Chen C, Chiang E, Chilcote JK, Dawson RI, Dong R, Doyon R, Draper ZH, Duchêne G, Esposito TM, Fabrycky D, Fitzgerald MP, Follette KB, Fortney JJ, Gerard B, Goodsell S, Greenbaum AZ, Hibon P, Hinkley S, Cotten TH, Hung LW, Ingraham P, Johnson-Groh M, Kalas P, Lafreniere D, Larkin JE, Lee J, Line M, Long D, Maire J, Marchis F, Matthews BC, Max CE, Metchev S, Millar-Blanchaer MA, Mittal T, Morley CV, Morzinski KM, Murray-Clay R, Oppenheimer R, Palmer DW, Patel R, Perrin MD, Poyneer LA, Rafikov RR, Rantakyrö FT, Rice EL, Rojo P, Rudy AR, Ruffio JB, Ruiz MT, Sadakuni N, Saddlemyer L, Salama M, Savransky D, Schneider AC, Sivaramakrishnan A, Song I, Soummer R, Thomas S, Vasisht G, Wallace JK, Ward-Duong K, Wiktorowicz SJ, Wolff SG, Zuckerman B.

Science. 2015 Oct 2;350(6256):64-7. doi: 10.1126/science.aac5891. Epub 2015 Aug 13.

16.

Helenalin bypasses Bcl-2-mediated cell death resistance by inhibiting NF-κB and promoting reactive oxygen species generation.

Hoffmann R, von Schwarzenberg K, López-Antón N, Rudy A, Wanner G, Dirsch VM, Vollmar AM.

Biochem Pharmacol. 2011 Sep 1;82(5):453-63. doi: 10.1016/j.bcp.2011.05.029. Epub 2011 Jun 2.

PMID:
21669190
17.

In silico discovery of acylated flavonol monorhamnosides from Eriobotrya japonica as natural, small-molecular weight inhibitors of XIAP BIR3.

Pfisterer PH, Shen C, Nikolovska-Coleska Z, Schyschka L, Schuster D, Rudy A, Wolber G, Vollmar AM, Rollinger JM, Stuppner H.

Bioorg Med Chem. 2011 Jan 15;19(2):1002-9. doi: 10.1016/j.bmc.2010.10.046. Epub 2010 Oct 25.

PMID:
21087868
18.

Neoandrographolide from Andrographis paniculata as a potential natural chemosensitizer.

Pfisterer PH, Rollinger JM, Schyschka L, Rudy A, Vollmar AM, Stuppner H.

Planta Med. 2010 Oct;76(15):1698-700. doi: 10.1055/s-0030-1249876. Epub 2010 May 5.

PMID:
20446243
19.

The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis.

Rothmeier AS, Schneiders UM, Wiedmann RM, Ischenko I, Bruns CJ, Rudy A, Zahler S, Vollmar AM.

Int J Cancer. 2010 Sep 1;127(5):1096-105. doi: 10.1002/ijc.25241.

20.

BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells.

Schneiders UM, Schyschka L, Rudy A, Vollmar AM.

Mol Cancer Ther. 2009 Oct;8(10):2914-25. doi: 10.1158/1535-7163.MCT-08-1179. Epub 2009 Oct 6.

21.

A multicenter, open-label, exploratory dose-ranging trial of intranasal hydromorphone for managing acute pain from traumatic injury.

Wermeling DP, Clinch T, Rudy AC, Dreitlein D, Suner S, Lacouture PG.

J Pain. 2010 Jan;11(1):24-31. doi: 10.1016/j.jpain.2009.05.002. Epub 2009 Jul 9.

PMID:
19592310
22.

A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation.

Wermeling DP, Record KA, Archer SM, Rudy AC.

Epilepsy Res. 2009 Feb;83(2-3):124-32. doi: 10.1016/j.eplepsyres.2008.10.005. Epub 2008 Nov 29.

PMID:
19046855
23.

Role of Smac in cephalostatin-induced cell death.

Rudy A, López-Antón N, Barth N, Pettit GR, Dirsch VM, Schulze-Osthoff K, Rehm M, Prehn JH, Vogler M, Fulda S, Vollmar AM.

Cell Death Differ. 2008 Dec;15(12):1930-40. doi: 10.1038/cdd.2008.125. Epub 2008 Sep 19.

24.

Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study.

Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP.

Pharmacotherapy. 2008 Jul;28(7):875-82. doi: 10.1592/phco.28.7.875.

PMID:
18576902
25.

Spongistatin 1: a new chemosensitizing marine compound that degrades XIAP.

Schyschka L, Rudy A, Jeremias I, Barth N, Pettit GR, Vollmar AM.

Leukemia. 2008 Sep;22(9):1737-45. doi: 10.1038/leu.2008.146. Epub 2008 Jun 12.

PMID:
18548102
26.

The cephalostatin way of apoptosis.

Rudy A, López-Antón N, Dirsch VM, Vollmar AM.

J Nat Prod. 2008 Mar;71(3):482-6. doi: 10.1021/np070534e. Epub 2008 Feb 8. Review.

PMID:
18257532
27.

[Diagnostic difficulties in adrenal incidentaloma--analysis of 125 cases].

Myśliwiec J, Rudy A, Siewko K, Myśliwiec P, Pułka M, Górska M.

Endokrynol Pol. 2007 Sep-Oct;58(5):417-21. Polish.

PMID:
18058737
28.

Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis.

Davis GA, Rudy AC, Archer SM, Wermeling DP, McNamara PJ.

Clin Drug Investig. 2004;24(11):633-9.

PMID:
17523726
29.

The marine product cephalostatin 1 activates an endoplasmic reticulum stress-specific and apoptosome-independent apoptotic signaling pathway.

López-Antón N, Rudy A, Barth N, Schmitz ML, Pettit GR, Schulze-Osthoff K, Dirsch VM, Vollmar AM.

J Biol Chem. 2006 Nov 3;281(44):33078-86. Epub 2006 Aug 31. Erratum in: J Biol Chem. 2006 Dec 22;281(51):39740. Schmitz, Lienhard M [corrected to Schmitz, M Lienhard].

30.

Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers.

Wermeling DP, Record KA, Kelly TH, Archer SM, Clinch T, Rudy AC.

Anesth Analg. 2006 Aug;103(2):344-9, table of contents.

PMID:
16861415
31.

Pharmacokinetics, bioequivalence, and spray weight reproducibility of intranasal butorphanol after administration with 2 different nasal spray pumps.

Wermeling DP, Miller JL, Archer SM, Rayens MK, Rudy AC.

J Clin Pharmacol. 2005 Aug;45(8):969-73. No abstract available.

PMID:
16027409
32.

Homocysteine concentrations and vascular complications in patients with type 2 diabetes.

Rudy A, Kowalska I, Straczkowski M, Kinalska I.

Diabetes Metab. 2005 Apr;31(2):112-7.

PMID:
15959416
34.

Cephalostatin 1 inactivates Bcl-2 by hyperphosphorylation independent of M-phase arrest and DNA damage.

Müller IM, Dirsch VM, Rudy A, López-Antón N, Pettit GR, Vollmar AM.

Mol Pharmacol. 2005 May;67(5):1684-9. Epub 2005 Feb 9.

35.

Bioavailability of intranasal butorphanol administered from a single-dose sprayer.

Davis GA, Rudy AIa, Archer SM, Wermeling DP.

Am J Health Syst Pharm. 2005 Jan 1;62(1):48-53.

PMID:
15658072
36.

A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers.

Rudy AC, Coda BA, Archer SM, Wermeling DP.

Anesth Analg. 2004 Nov;99(5):1379-86; table of contents.

PMID:
15502034
37.

Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer.

Davis GA, Rudy AC, Archer SM, Wermeling DP.

Am J Health Syst Pharm. 2004 Feb 1;61(3):261-6.

PMID:
14986556
38.

Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis.

Davis GA, Rudy AC, Archer SM, Wermeling DP, McNamara PJ.

Pharmacotherapy. 2004 Jan;24(1):26-32.

PMID:
14740785
39.

Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers.

Coda BA, Rudy AC, Archer SM, Wermeling DP.

Anesth Analg. 2003 Jul;97(1):117-23, table of contents.

PMID:
12818953
40.

Hydromorphone transfer into breast milk after intranasal administration.

Edwards JE, Rudy AC, Wermeling DP, Desai N, McNamara PJ.

Pharmacotherapy. 2003 Feb;23(2):153-8.

PMID:
12587803
41.

Pulmonary neuroendocrine cells in physiology and pathology.

Rydzewska-Rosołowska AE, Kasacka I, Sulewska A, Rudy A, Chyczewski L.

Folia Histochem Cytobiol. 2001;39 Suppl 2:58-63. Review.

PMID:
11820629
42.

Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration.

Wermeling DP, Miller JL, Archer SM, Manaligod JM, Rudy AC.

J Clin Pharmacol. 2001 Nov;41(11):1225-31.

PMID:
11697755
43.

Helicobacter pylori vacA genotypes and cagA gene in a series of 383 H. pylori-positive patients.

Rudi J, Kuck D, Rudy A, Sieg A, Maiwald M, Stremmel W.

Z Gastroenterol. 2000 Jul;38(7):559-64.

PMID:
10965552
44.

Direct determination of Helicobacter pylori vacA genotypes and cagA gene in gastric biopsies and relationship to gastrointestinal diseases.

Rudi J, Rudy A, Maiwald M, Kuck D, Sieg A, Stremmel W.

Am J Gastroenterol. 1999 Jun;94(6):1525-31.

PMID:
10364019
45.

Helicobacter sp. are not detectable in bile from German patients with biliary disease.

Rudi J, Rudy A, Maiwald M, Stremmel W.

Gastroenterology. 1999 Apr;116(4):1016-7. No abstract available.

PMID:
10092334
46.

Stereoselective pharmacokinetics and inversion of (R)- ketoprofen in healthy volunteers.

Rudy AC, Liu Y, Brater C, Hall SD.

J Clin Pharmacol. 1998 Feb;38(2S):3S-10S.

PMID:
9549653
47.

In vivo absorption of aluminium-containing vaccine adjuvants using 26Al.

Flarend RE, Hem SL, White JL, Elmore D, Suckow MA, Rudy AC, Dandashli EA.

Vaccine. 1997 Aug-Sep;15(12-13):1314-8.

PMID:
9302736
48.

The Influence of Misoprostol on the Adverse Renal Effects and Stereospecific Pharmacokinetics of Ibuprofen in Chronic Renal Insufficiency.

Rudy DW, Rudy AC, Black PK, Liu Y, Hamman M, Brater DC.

Am J Ther. 1995 Nov;2(11):864-874.

PMID:
11854800
49.

Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment.

Rudy AC, Knight PM, Brater DC, Hall SD.

J Pharmacol Exp Ther. 1995 Apr;273(1):88-93.

PMID:
7714818
50.

The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.

Rudy AC, Figueroa NL, Hall SD, Brater DC.

Br J Clin Pharmacol. 1994 Jan;37(1):1-5.

Supplemental Content

Support Center